Avnish Tripathi
Interventional Cardiology · Gresham, ORNPI 1801150214
Payments from drug & device makers
What this record shows
37 manufacturers reported payments, led by Medtronic at 42.0% of the total.
Across 279 payments — averaging $46.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Philips North America LLC$1K
- Terumo Medical Corporation$1K
- Boston Scientific$789
- Abbott$777
- Abiomed$338
- plus $3K from 31 others
What the payments were for
- Travel & lodging$7,12054%
- Food & beverage$5,98946%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 66 | $5,507 |
| Philips North America LLC | 7 | $1,230 |
| Terumo Medical Corporation | 9 | $1,164 |
| Boston Scientific | 34 | $789 |
| Abbott | 7 | $777 |
| Abiomed | 7 | $338 |
| Johnson & Johnson | 22 | $303 |
| Cardiovascular Systems Inc. | 4 | $278 |
| Novartis | 15 | $251 |
| Avinger Inc. | 3 | $246 |
| Inari Medical, Inc. | 6 | $229 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $213 |
| Amgen | 14 | $199 |
| E.r. Squibb & Sons, L.L.C. | 3 | $160 |
| AstraZeneca | 7 | $146 |
| Novo Nordisk | 5 | $138 |
| Chiesi USA, Inc. | 10 | $136 |
| Penumbra, Inc. | 3 | $131 |
| Cordis US CORP. | 2 | $110 |
| Amarin Pharma, Inc. | 5 | $100 |
| Shockwave Medical, Inc | 4 | $83 |
| Pfizer | 5 | $79 |
| Edwards Lifesciences | 3 | $78 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $74 |
| Merck | 5 | $67 |
| Baxter Healthcare | 1 | $44 |
| Alnylam Pharmaceuticals Inc. | 2 | $42 |
| Heartflow, Inc. | 1 | $34 |
| Boehringer Ingelheim | 2 | $28 |
| EKOS Corporation | 2 | $26 |
| Irhythm Technologies, Inc. | 1 | $18 |
| Teleflex LLC | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Stryker | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Cook Medical LLC | 1 | $15 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADVISA DR MRI SURESCAN$2,968
- US Und$1,114
- Navicross$938
- Glidesheath$938
- GlideWire$938
- VenaSeal$884
- Perclose ProStyle$673
- Coronary Orbital Atherectomy System$227
- HawkOne$209
- PANTHERIS$142
- Impella$127
- ELIQUIS$117
How this compares
$13,109 in reported general payments places this provider in the 70th percentile of 68 interventional cardiology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 167 | $138,846 |
| EntrestoSacubitril/Valsartan | 50 | $40,493 |
| JardianceEmpagliflozin | 27 | $19,681 |
| BrilintaTicagrelor | 35 | $19,355 |
| XareltoRivaroxaban | 22 | $18,411 |
| FarxigaDapagliflozin Propanediol | 22 | $15,204 |
| Atorvastatin Calcium | 291 | $2,917 |
| Metoprolol Succinate | 198 | $2,213 |
| ClopidogrelClopidogrel Bisulfate | 155 | $1,705 |
| Losartan Potassium | 131 | $1,458 |
| Carvedilol | 190 | $1,050 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 127 | $1,036 |
| Ezetimibe | 60 | $865 |
| Furosemide | 171 | $781 |
| Amlodipine Besylate | 119 | $600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $79 | $138,846167 claims |
| NovartisEntresto | $251 | $40,49350 claims |
| AstraZenecaBrilinta, Farxiga | $146 | $34,55957 claims |
| Boehringer IngelheimJardiance | $28 | $19,68127 claims |
| Johnson & JohnsonXarelto | $303 | $18,41122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 68 interventional cardiology providers in Oregon.
Other interventional cardiology in Gresham
- Jason WollmuthPortland$749K
- Saurabh GuptaBend$550K
- Ethan KorngoldPortland$407K
- Amish DesaiPortland$186K
- Harsh GolwalaPortland$105K
- Brandon JonesPortland$101K
- Sudeshna BanerjeeSpringfield$66K
- Kathryn DawsonPortland$57K
- Kevin ThompsonSalem$56K
- Logan VincentPortland$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.